A Study of NTX-1472 in Social Anxiety Disorder

Summary

The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: Is NTX-1472 safe and well tolerated in adults with SAD? How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: Take NTX-1472 or matching placebo every day for 8 weeks Visit the clinic 6 times over the course of 14 weeks for checkups and tests

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Social Anxiety Disorder (SAD)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Newleos Therapeutics, Inc.

Last updated on ClinicalTrials.gov

July 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites